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Abstract
Background: Household contact tracing of index TB cases has been advocated as a key part of TB control for
many years, but has not been widely implemented in many low-resource setting because of the current dearth of
high quality evidence for effectiveness. Innovative strategies for earlier, more effective treatment are particularly
important in contexts with hyper-endemic levels of HIV, where levels of TB infection remain extremely high.
Methods: We present the design of a household cluster-randomised controlled trial of interventions aimed at
improving TB-free survival and reducing childhood prevalence of Mycobacterium tuberculosis infection among
household contacts of index TB cases diagnosed in two provinces of South Africa. Households of index TB cases
will be randomly allocated in a 1:1 ratio to receive either an intensified home screening and linkage for TB and HIV
intervention, or enhanced standard of care. The primary outcome will compare between groups the TB-free survival
of household contacts over 15 months. All participants, or their next-of-kin, will provide written informed consent to
participate.
Discussion: Evidence from randomised trials is required to identify cost-effective approaches to TB case-finding
that can be applied at scale in sub-Saharan Africa.
Trial registration: ISRCTN16006202 (01/02/2017: retrospectively registered) and NHREC4399 (11/04/2016:
prospectively registered). Protocol version: 4.0 (date: 18th January 2018).
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Background
Tuberculosis (TB) remains a public health priority, and
is now the leading adult infectious cause of death world-
wide [1]. In sub-Saharan Africa, TB incidence rates have
skyrocketed [1, 2], driven principally by extremely high
prevalence of human immunodeficiency virus (HIV) in-
fection [2]. South Africa is the country with the largest
number of people living with HIV worldwide [3], and
has experienced extremely high TB incidence, preva-
lence and TB-related mortality [4].
The End-TB Strategy calls for bold action to eliminate
tuberculosis as a public health issue by 2035 [5]. Central
to the End-TB strategy is a recognition that integrated
patient-centred care is required to treat all cases of tu-
berculosis, along with systematic screening of contacts
and other high-risk groups to provide effective prevent-
ive interventions [5]. Moreover, high out-of-pocket costs
of care-seeking and treatment have proved to be cata-
strophic for many people attempting to accesses TB care
and treatment [6, 7]. Interventions that can deliver earl-
ier, equitable, affordable and effective TB and HIV diag-
nosis and treatment are urgently required.
Rationale for trial
Contact tracing of index TB cases (sometimes known as
“sentinel” or “source” cases) has been advocated as a key
part of TB control for many years because it facilitates
early identification of symptomatic and infectious linked
cases, and allows individuals with TB infection to receive
preventive treatment [8–10]. Although, World Health
Organization (WHO) [10] and National Guidelines in
South Africa [11] recommend household contact tracing,
the 2012 WHO guidelines have not been prioritized or
widely implemented in South Africa (or indeed in many
other high TB burden countries) because of the limited
available evidence for effectiveness or cost-effectiveness
[12], and the requirement to reallocate resources in
many settings that are already struggling to identify,
diagnose and treat people with TB symptoms [13].
The Zambia, South Africa Tuberculosis and AIDS Re-
duction (ZAMSTAR) community randomized trial in
Zambia and South Africa [14] has shown that household
contact tracing has the potential to reduce new TB infec-
tions in young children and TB prevalence in communities,
whereas untargeted community TB case finding interven-
tion also tested in ZAMSTAR had no impact on these
outcomes. The ZAMSTAR household contact tracing
intervention comprised of: identification of target house-
holds through adult index TB cases; symptom screening of
household contacts to identify individuals for further TB
investigation; testing symptomatic individuals using sputum
smear microscopy. To date, the ZAMSTAR study team has
not reported on process and outcome indicators of the
household intervention, such as: the rates of newly
diagnosed TB disease and/or HIV infection in contacts who
accessed care and prevention services; the number of times
that the entire household was offered TB symptom screen-
ing; the proportion of contacts who should have received
TB preventive treatment and/or antiretroviral therapy
(ART), and who actually received it; and the costs of imple-
menting this strategy its cost effectiveness in relation to
passive case finding. Additionally, the symptom-based, spu-
tum smear screening strategy used in ZAMSTAR to iden-
tify and investigate TB suspects likely missed some
household contacts with prevalent infectious TB [15],
thereby limiting the effectiveness of the household interven-
tions. Moreover, at the time of the trial ART - a potent
means of preventing TB disease - was not universally avail-
able, with initiation of ART based on cluster of differenti-
ation 4 (CD4) cell count thresholds.
Our prior studies in households of adult and paediatric
index TB cases in two different South African settings
where HIV prevalence is high, indicate that a substantial
proportion of household contacts who have sputum cul-
tures positive for M. tuberculosis do not report symp-
toms and, under the ZAMSTAR strategy, would not
have been identified by symptom screening [16, 17].
Moreover, data from the Vhembe Health District in
Limpopo, South Africa (a relatively low TB incidence
area) showed that household contact tracing identified
comparable rates of undiagnosed TB disease in contacts
as in the high TB incidence area (or “hot spot” area) of
Matlosana District; again, a significant proportion of
contacts with newly identified culture-positive TB dis-
ease reported no symptoms [18].
Mathematical models emphasize that the failure to detect
contacts with asymptomatic or subclinical TB limits the
potential reduction on community TB transmission [19]
and suggest that earlier identification and prompt treatment
of contacts could result in improved population-level TB
control [19].
Compared to sputum culture and the newer molecular
TB diagnostics, sputum smear has reduced sensitivity in
HIV-infected individuals because of the paucibacillary na-
ture of early TB disease [20]. Since the final ZAMSTAR
prevalence survey in 2010, routine TB diagnostics have im-
proved markedly with the widespread scale-up of the Xpert
MTB/Rif molecular TB diagnostic platform, which is more
sensitive and specific than sputum smear in diagnosing TB
[21]. Importantly, Xpert reduces diagnostic delay and allows
for earlier TB treatment initiation [22]. TB preventive treat-
ment guidelines for HIV-infected individuals now recom-
mend long-term, more effective and safe regimens [23, 24],
which when co-administered with antiretroviral therapy
(ART) reduce mortality and TB disease [25, 26]. WHO has
recommended a “test-and-treat” with immediate ART initi-
ation for all individuals living with HIV [27]; first line ART
regimens have been simplified to single daily dosing with
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fixed-dose combination tablets [27]. Moreover, children di-
agnosed with TB are increasingly being recognized as im-
portant sentinel cases for rapid identification of an
infectious household TB case [17, 28] and equally import-
antly, for identifying undiagnosed or untreated maternal
HIV infection. Finally, our data shows that HIV-
seronegative household contacts in a high burden setting in
the year after a household contact tracing intervention had
annual TB incidence of 700/100,000 [29]. This is consider-
ably higher than in most HIV-seronegative individuals and
suggests preventive treatment against TB should be offered
to HIV seronegative adults and older children, although not
currently part of guidelines for preventive treatment against
TB in South Africa.
We therefore hypothesise that an intensified house-
hold contact tracing and treatment support intervention
that includes these diagnostic and preventative advances
will improve TB-free survival among household contacts,
and will decrease the prevalence of TB infection in
children.
Methods/design
Study design
A household cluster randomised trial.
Study setting
The study is being conducted in two South African Dis-
tricts, selected based primarily on their differing TB and
HIV burden and existing community research links (Bot-
shabelo Subdistrict, Mangaung Metropolitan Municipality
in the Free State, population, 2011 population: 181,712
[30]; and the Capricorn Health District in Limpopo Prov-
ince, 2011 population: 1,293,000 [31]) – map: Additional
file 1: Figure S1. The antenatal HIV seroprevalence and the
annual TB incidence for 2012 in Mangaung Municipality
and in the Capricorn Health District were 32% and 686/
100,000 and 15% and 371/100,000 respectively [32, 33].
These two settings provide valuable information on the
intervention when implemented in a TB “hot spot” com-
pared to one with a lower annual TB burden.
Identification of index TB cases
Index TB cases eligible to participate in the study will be
any patient (living or recently deceased within 6 weeks
of confirmed TB diagnosis) who is a permanent resident
of one of the study districts with no plans to relocate
over the planned duration of the study, and who has
been diagnosed with TB. In index cases older than 7
years, only those with laboratory confirmed pulmonary
TB were eligible; if 7 years or younger, we will include
patients with TB diagnosed by a doctor without bac-
teriological confirmation, or bacteriologically-confirmed
TB of any organ. Index cases will be diagnosed at any
health facility in the study districts in the 6 weeks prior
to recruitment. Severely ill and deceased patients will be
included as index cases if we obtain written informed
consent from a close family member. Severely ill patients
with TB will be requested to confirm their participation
in the study once they are capable of providing informed
consent. We will exclude individuals who are incarcer-
ated or are in long term in-patient care for reasons apart
from TB.
Research teams will identify potentially eligible index
TB cases by visiting hospital wards and clinics, from
routine reporting of TB cases in public-sector health fa-
cilities in the two study districts (TB registers and notifi-
cations), and from lists of specimens positive for TB
generated by public sector laboratories.
For each index TB case who provides informed con-
sent, a baseline questionnaire will be completed; in
paediatric index cases or where the index case is de-
ceased or too ill to provide informed consent, this infor-
mation will be obtained from the caregiver or
participant’s representative. Additionally, we will ask
index cases – or their representative – to complete a
line-list of all household members.
Design of interventions
The households of index TB cases will be randomly allo-
cated in a 1:1 ratio to one of two interventions: intensi-
fied household contact tracing and treatment support
(intervention); or enhanced standard of care (control).
Randomisation, allocation and blinding
The unit of randomization is households of recruited
index TB cases. The dwelling within which the house-
hold members live is defined as all rooms under a con-
tiguous roofed area linked by doorways or windows
through which air can pass. For this study, household
members are defined as all individuals who shared
dwelling airspace by either having slept overnight at least
once, or shared at least two meals in the same household
as the index case in the 14 days prior to the index case’s
diagnosis of TB.
Index cases and their household members will be ran-
domly allocated using a computer-generated allocation
sequence stratified by district and with a block size of 10
generated prior to the first allocation by the study statis-
tician. For each index case at both sites, allocation is
accessed through a central study telephone line, staffed
by a data manager in Johannesburg, unlinked to other
aspects of the study. Randomisation only occurs after
consent procedures and baseline questionnaires and
after all eligibility criteria have been satisfied.
This is an open study as we cannot blind index cases,
their households, or study field research teams to allocation.
However, study research assistants are blinded to the
allocation of households when they conduct outcome
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assessments, and investigator blinding will be maintained
until final analysis; no interim analyses which reveal results
of the study or provide an indication by group laboratory
results, or other outcomes, will be provided to site staff or
investigators.
Intensified household contact tracing and treatment
support (intervention group)
In households allocated to the intervention group, within
14 days of recruiting the index TB case, a research team
comprising of an enrolled nurse and counsellors will
conduct an initial household visit, record characteristics
of the dwelling, seek consent to participate from all
household members, and administer a short question-
naire to each recruited household member that will in-
clude: demographic details including relationship and
exposure to the recruited index case; risk factors for TB;
presence of TB symptoms; and history of previous and
current HIV and TB treatment.
All household members will be offered confidential
HIV testing and counselling in accordance with South
African guidelines - or anonymised testing for study pur-
poses if consent for this is provided - followed by blood
sampling for CD4 cell count measurement in household
members diagnosed HIV-infected. We will collect one
spot sputum sample from each household member cap-
able of producing a sputum sample (irrespective of the
presence of TB symptoms), which will be transported to
the public sector laboratory at each site, and tested using
the GeneXpert MTB/Rif platform until approximately
the end of 2017, when the Xpert Ultra was rolled out na-
tionally in South Africa. Sputa will also be cultured using
the liquid Mycobacteria growth indicator tube (MGIT)
platform. Tuberculin skin testing (TST) will be offered
to all household members without confirmed TB.
At a follow-up household visit 1 week later, results of spu-
tum Xpert testing will be communicated in confidence to
household members. Participants with microbiologically-
confirmed tuberculosis or HIV requiring care and treatment
will be supported to attend their nearest local primary care
clinic to register for care and treatment. Household members
will be offered isoniazid preventive therapy (IPT) according
to South African guidelines - which have changed over the
course of the trial (in brief those who test HIV-positive and
whose sputum tests are negative for TB or those who are
under 5 years of age). Additionally, we will offer IPT to HIV-
seronegative individuals whose tuberculin skin test is positive
(≥10mm), and who agree to take isoniazid preventive treat-
ment. Patients who accept isoniazid preventive treatment are
dispensed the first month of isoniazid preventive therapy by
study nurses at their home, and are referred for ongoing pre-
ventive treatment at their local clinics.
Because previous studies have demonstrated subopti-
mal rates of linkage into TB and HIV care [34, 35], a re-
visit will be conducted 3 months after recruitment to
support access to health facilities where required. If
there has been no response to accessing care by individ-
uals in a household, the local clinic will be approached
to visit the household and take over their care.
Enhanced standard of care (control group)
Each recruited index case – or their representative – al-
located to the enhanced standard of care group will be
provided with a referral letter and information materials
for every household member they identify at baseline
interview, and will be requested to give a pre-printed re-
ferral letter to each person in their household. The refer-
ral letter contains information about TB and HIV,
recommends screening for TB and HIV, and provides
details of local health facilities where screening and fur-
ther care (if required) may be accessed. Additionally, the
referral letter contains directions for health providers,
including recommendations that TB screening, HIV test-
ing and further care and prevention services (including
ART and TB preventive therapy as required) should be
offered in accordance with South African National
guidelines because the individual was exposed to a likely
infectious case of TB.
A week after recruitment, study research assistants will
attempt to make a follow up telephone call to the index
case, or their caregiver, to ensure the referral letters were
given to household members, and to confirm that any ill
household members have accessed their local health
facility.
Outcome measures
The primary outcome of the trial is a composite one:
TB-free survival in the household starting 1 month after
randomisation to the final ascertainment visit (an
expected total follow-up time of ~ 14months); the one-
month lead-in time is to allow evaluation of the prevent-
ive effect of the study interventions, by excluding from
analysis incident TB diagnoses that occur between
months 0 and 1 that would likely detected as part of the
intensified investigations in the intervention households.
The follow-up time for those reaching the endpoint will
be the time from a month after randomisation, or date
of becoming a permanent household member (if entered
the household at least 1 month after randomisation) to
date of loss to follow-up or the date of the 15-month
final outcome ascertainment visit; the follow-up time for
those not reaching the endpoint will be the time from 1
month after randomisation or date of becoming a per-
manent household member (if entered the household at
least 1 month after randomisation) to date of tubercu-
losis diagnosis or to date of death (or if both occur dur-
ing the follow-up, the earliest of these). All analyses will
be done using two different definitions of TB: (1)
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including all cases where TB was diagnosed or TB treat-
ment started, irrespective of the diagnostic method (“all
TB”); (2) including only those where hard copy of a la-
boratory confirmation of TB was seen by the study team
or for whom there is written medical record confirm-
ation of a positive laboratory test for TB (“microbiologic-
ally-confirmed TB”).
Secondary outcomes, together with their definitions,
are:
1) Prevalence of TB infection at month 15 visit among
household children who are aged under 14 years of
age at the month 15 visit: Measured by tuberculin
skin test (TST) reactivity – defined in three ways:
a) TST diameter ≥ 10mm (irrespective of HIV
serostatus or other comorbid condition) at the
month 15 visit. This is our main definition of
interest for this key secondary outcome.
b) TST diameter ≥ 15mm in all participants
irrespective of HIV serostatus, or other
comorbid conditions at the month 15 visit. This
is likely to be more specific.
c) Differential TST diameter: ≥5 mm in HIV
infected children and in children who are
underweight (defined as either height for age or
weight for age Z-score of <− 2); TST diameter ≥
10 mm in seronegative and non- malnourished
children.
We will also report the distribution of TST readings in
children < 14 years, and the estimated annual risk of TB
infection (ARI).
2) Time between first onset of symptoms and
initiation of anti-tuberculosis treatment, among
household members diagnosed with TB between
baseline and month 15 visit
3) HIV prevalence (reported as a percentage of those
HIV-tested at the month 15 visit) of previously un-
diagnosed, or previously diagnosed, but untreated
HIV infection
4) Cumulative incidence of all-cause mortality at the
month 15 visit
5) HIV viral load, defined as the prevalence of
detectable viraemia (> 400 copies per/ml) within
each trial arm (should we have sufficient data from
HIV-infected individuals to do this)
6) Estimation of the cost-effectiveness of the in-
tensified household contact tracing and treat-
ment support intervention compared to the
enhanced standard of care from a societal
perspective. Analyses for this outcome will be
described in a separate economic statistical
analysis plan.
Subgroup analyses
1. Subgroup analysis by study site (Capricorn District
and Botshabelo District) will be conducted for all
outcomes, in order to assess whether the effect of
the intervention differs between a high (Botshabelo)
and lower (Capricorn) TB burden setting.
2. For the secondary outcome of TB infection as
assessed by TST reactivity among children aged <
14 years, we will conduct a subgroup analysis
comparing children < 5 years of age with those aged
≥5 years at the month 15 visit.
Outcome assessment
We will conduct an outcome household visit to all
households, irrespective of their study allocation, at 15
months after the recruitment of the index case. Two
months prior to the visit, we will attempt to locate the
standard of care households (that have not been visited
prior to this time) using a What3Words a mapping ap-
plication – this to reduce the potential bias of travelling
directly to the household versus attempting to find
households for the first time at the outcome visit. More-
over, to reduce potential bias, study teams that have not
visited that intervention household previously will be
used to conduct the outcome visit.
At the outcome visit, Research Assistants blinded to
the original allocation of the household will 1) trace all
household participants, ascertain vital status and attempt
to assess whether those who died, died with TB and/or
HIV; 2) record episodes of TB and first HIV diagnosis,
treatment and other hospitalizations from verbal report
and inspection of patient-held records; 3) investigate
participants with symptoms of TB (any of: cough, fever,
weight loss, night sweats) by collecting sputum for smear
microscopy, sputum culture for M. tuberculosis and
Xpert; 4) offer repeat HIV testing to participants nega-
tive or not previously tested at baseline; and 5) conduct
a prevalence survey for latent TB infection by testing all
children under 14 years old with the tuberculin skin test.
Health economics and cost-effectiveness
All costing and economic evaluations will be primarily
from the perspective of the health care system to en-
hance comparability with other studies. However, esti-
mates of household costs of illness and deaths will also
be included in certain cost effectiveness measures to re-
flect a societal perspective. The analysis will also explore
the magnitude of household costs, potential for cata-
strophic costs of HIV and TB, and implications for uni-
versal access.
We will use a direct costing approach to assess incremen-
tal costs of the intervention in achieving the primary object-
ive. This will consider costs of diagnostic investigations, staff
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and travel and any other substantial items that may be iden-
tified. Intervention costs will be differentiated carefully from
various services and also from research activities.
Interviews with household members will record direct
and indirect costs (e.g. lost income) of illness and acces-
sing healthcare, and about effect on various household
asset holdings to explore dissaving and potential for
catastrophic costs.
The principal cost effectiveness indicators will be in-
cremental costs per person diagnosed with HIV and/or
TB, incremental cost per person linked to HIV and/or
TB care through the intervention in each setting, and in-
cremental cost per incident TB case and death avoided.
Further indicators such as estimated incremental cost
per life-year saved or per TB treatment completion will
be generated if the frequency and profile of reported
clinical outcomes support this. In addition, we will
measure health-related quality of life of household mem-
bers at baseline and follow-up using the EuroQol EQ-5D
[36].
Records of health service utilization (in-patient days
and outpatient visits) for each group will be combined
with unit costs for each type of care derived from step-
down costings in relevant facilities to estimate possible
cost savings and net costs.
Incremental cost effectiveness ratios will be compared
to benchmarks for South African HIV, TB and other
health interventions to facilitate interpretation for
policymakers.
Sensitivity analyses will assess the strength and robust-
ness of cost effectiveness findings, and aggregated and
disaggregated unit cost measures will be reported. To
clarify comparisons with other interventions and rele-
vance for other settings, reports will clearly describe the
case finding initiative and context, and explore system
strengthening issues such as capacity needs, effects of
scale and overall budget requirements.
Statistical analysis plan
A sample size of 1200 index cases in each district (2400
in total) is proposed, based on previous studies in the
districts, and assuming mean household size of 5.5
members, and household TB incidence that is the mean
of that reported for each district. This will provide 80%
power to detect a 30% difference (two-sided p < 0.05) in
TB-free survival between the trial arms with an intra-
cluster correlation coefficient of k = 0.3. Routine data
from both sites suggest that they diagnose and treat at
least double this number of TB cases per annum. No in-
terim analysis will be undertaken.
Data will be captured using paper case record forms,
and doubled entered into a secure RedCap Database
hosted on a server at the University of Witwatersrand,
Johannesburg, South Africa. To maintain confidentiality
of participants, completed case record forms will be
stored securely at study site research offices, and partici-
pant identifying information will be removed during data
capture. Logical rules and check ranges for values will be
implemented, and data quality checks will be run regu-
larly by the study Data Manager.
All analysis will be done on an intention to treat basis,
with denominators comprising households and house-
hold members randomly allocated to trial groups. We
will compare baseline household-, and index case-, and
household members-level socio-demographic and clin-
ical characteristics between allocated trial groups. This
will use absolute numbers and proportions for categor-
ical variables. Means and standard deviations, or me-
dians and interquartile ranges, will be used for
continuous variables.
Outcomes will be assessed in two analysis populations:
A) all household members who were listed at baseline
for whom information is available at final study visit
(“baseline cohort”, with analysis including and excluding
TB index case conducted); B) all household members for
whom information is available at final study visit irre-
spective of presence at baseline (“final visit cohort”). Co-
hort A will be the primary analysis population. Results
from Cohort B will be used to investigate whether the
effect of the intervention extends beyond those exposed
to the intervention.
All analyses will be done on an intention-to-treat basis,
i.e. data from household members included in popula-
tions A and B described above, will be included in the
analysis, regardless of whether they underwent all inter-
vention procedures in their trial arm.
Additionally, for secondary outcome 1, the analysis
population will be restricted to those individuals aged
less than 14 years at the time of outcome assessment at
15 months and for secondary outcome 2, the analysis
population will be restricted to those individuals with a
bacteriologically-confirmed TB diagnosis during the
follow-up period.
For the primary trial outcome (TB free survival), Pois-
son regression with random effects to account for clus-
tering at the household level, will be used to estimate a
rate ratio, 95% confidence interval and p-value for the
effect of the intervention. To allow for the stratified ran-
domisation by district, a fixed effect term for district will
be included in the regression model.
Analysis of secondary and exploratory outcomes will
follow a similar approach, except where binomial out-
comes are assessed (e.g. proportion of child household
members with MTB infection; proportion of household
members with undiagnosed or untreated HIV), in which
case we will use logistic regression with random effects
to account for household clustering. For secondary out-
come 5 (community HIV load), we will calculate this as
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the fraction of HIV-positive individuals with a measured
viral load who have detectable viraemia multiplied by
the number of individuals testing HIV-positive and di-
vided by the total population with a measured HIV
status.
Subgroup analysis will be done by examining stratum-
specific (district-specific) rate ratios (or odds ratios for
binary outcomes) and by fitting terms for the interaction
between trial arm and district in random effects regres-
sion models.
This trial offers a number of important health benefits,
including early diagnosis and supported access to TB
and HIV care, which are known to be problematic and
expensive for individuals under current health systems
in South Africa. Moreover, the trial will provide import-
ant information to assist in the development of im-
proved HIV and TB services and pathways to care in
local communities and in South Africa.
All index TB cases (or their representative if deceased)
and household members will provide informed consent
to participate in the study. Parental consent to partici-
pate in research will be obtained for children < 18 years
and assent will be obtained from children 7-14 years. In-
dividuals who are illiterate, or unable to write, will be in-
vited to provide a thumbprint confirmation of consent
to participant, accompanied by a witness signature.
Household tracing has the potential to inadvertently
disclose confidential clinical information such as TB or
HIV status, and to perpetrate stigma and discrimination,
although previous cluster randomised trials in sub-
Saharan Africa have demonstrated that these potential
risks are minimal, with trial withdrawal due to stigma or
discrimination extremely uncommon [37, 38]. Partner
disclosure of HIV status and TB status have been clearly
shown to be beneficial to household members and part-
ners. Nevertheless, the trial team will take extensive
steps to ensure that recruited index cases are fully aware
of the possible implications of household tracing and
follow-up, and they will be supported to disclose results
to members of their household by trained research assis-
tants and study nurses. HIV and TB testing will use
South African National guideline procedures, which have
been well-validated in terms of diagnostic accuracy.
Discussion
The TB and HIV co-epidemics in sub-Saharan Africa
continue to pose serious threats to public health, health
systems and development. The End-TB Strategy has set
out bold targets to identify and treat all individuals with
TB to rapidly reduce incidence, prevalence, morbidity,
and mortality, and eliminate the catastrophic costs asso-
ciated with TB diagnosis and treatment [5]. Concerted
action is underway to implement high impact HIV care
and prevention to end the acquired immunodeficiency
syndrome (AIDS) epidemic. Despite primary data [16,
17, 28], systematic reviews [12, 21] and guidelines [10]
highlighting the high potential of index-case based case
finding interventions for TB and HIV, implementation
in the region has been limited by a lack of clear evidence
on how cost-effective interventions are likely to be for
households, communities and health systems. The
present cluster-randomised trial will attempt to answer a
series of critical outstanding questions for policymakers:
can a strategy of household index TB case contact tra-
cing, intensified screening for HIV and TB (with rapid
molecular testing of all contacts), and supported linkage
into HIV and TB treatment and prevention improve TB-
free survival and reduce prevalence of M. tuberculosis in-
fection in children?
Historically, household contact tracing of index TB
cases – with an emphasis on prompt identification,
screening and treatment of contacts of sputum-smear
positive cases – has contributed to the substantial im-
provements in TB control over the twentieth century.
This strategy is still widely used in high income settings
[39]. However, concerns over resource-requirements and
affordability have precluded implementation in low in-
come settings. Moreover, where TB incidence and preva-
lence are high, and in high HIV prevalence settings,
concerns have been raised that household-targeted case-
finding approaches may be ineffective as incident TB
disease among household contacts comprises only a
small fraction of all population TB cases, meaning that
household-targeted screening may only contribute mar-
ginally to case detection and overall reductions in dis-
ease incidence and prevalence [40]. Indeed, the
ZAMSTAR trial did not clearly demonstrate the effect-
iveness of household-based interventions on reducing
community TB prevalence and incidence of childhood
infection [14]. However, coupled with emerging evidence
of the higher than previously thought burden of previ-
ously undiagnosed HIV and TB among household con-
tacts of TB cases [16], a number of new advances in
more sensitive rapid molecular TB diagnostics (e.g.
Xpert MTB/Rif), and increasing awareness of the effect-
iveness of longer duration TB chemoprophylaxis and
ART have given fresh impetus to evaluate the effective-
ness of more intensified household approaches.
Considerable uncertainty exists about where TB is pre-
dominantly transmitted in high HIV prevalence settings.
Social mixing and genomic studies suggest that only a
moderate fraction of transmissions occur within house-
holds, with settings outside the house such as churches,
bars and public transport more commonly implicated
[41–44]. Nevertheless, there remains a compelling public
health and epidemiological case for targeting contact tra-
cing towards the household contacts of index TB cases.
Despite incident cases being infrequently linked by
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existing techniques at the population level, cohort stud-
ies have demonstrated that the risk of incident and
prevalent TB is substantially and significantly higher
among household contacts than among individuals not
exposed to the household [29]. Moreover, household
contacts are usually substantially easier to trace, screen
and support to access care, treatment and prevention
services than contacts encountered in other settings. As-
sessment of shared airspace exposure-time to potentially
infectious cases can be more readily made, informing a
more rational approach to screening criteria. Finally, the
extremely high prevalence and incidence of previously
undiagnosed and untreated HIV with high susceptible to
TB disease makes an integrated household TB and HIV
case-finding, screening, treatment and prevention ap-
proach feasible and attractive.
The units of randomisation in this trial are the house-
holds of index TB cases. In addition to facilitating deliv-
ery of trial interventions, the cluster-randomised design
will allow us to determine effectiveness on TB-free sur-
vival at the household level, allowing us to test hypoth-
eses around the impact on household-contacts. Should
the present trial demonstrate intervention effectiveness,
future trials may wish to investigate the effectiveness of
interventions on TB incidence, prevalence or mortality
at a community level. Such a cluster-randomised trial
would however be very expensive, requiring large num-
bers of participants and clusters to evaluate the com-
paratively rare TB endpoints. Therefore, the present trial
will provide important preliminary evidence on effective-
ness to inform the design of future trials.
Strengths of this trial include the efficient design to evalu-
ate the effectiveness on a number of important endpoints;
the high likelihood that results will be directly informative to
policymakers; and the potential to support capacity develop-
ment at health facilities and university departments in trad-
itionally under-resourced settings. There are however a
number of challenges in the design and implementation.
Despite recent advances, bacteriological TB diagnostics for
active disease remain suboptimal, and screening for latent
disease is limited by poor sensitivity, especially where envir-
onmental mycobacterial exposure and HIV are common.
Because incident TB cases in household contacts may be
bacteriologically-undetected, we will evaluate the effective-
ness of interventions on incidence rates of both
bacteriologically-confirmed and all-TB. Because of the na-
ture of trial interventions, it is impossible to blind partici-
pants to allocation group. To minimise the risk of bias,
research assistants conducting final outcome assessments
will be blinded to household allocation, and investigator
blinding will be maintained until the completion of all study
activities and final data preparation. We have selected one
very-high and one moderate TB incidence community for
study sites, however analysis will be underpowered to detect
differences in the impact of the intervention on outcomes
between sites. Results will be generalizable to similar com-
munities in sub-Saharan Africa, but may not be to other
lower HIV prevalence settings.
In summary, results of this trial will provide policy-
makers with clear evidence about whether intensified
household contact tracing of index TB cases, screening
for HIV and TB, and supported linkage to care, treat-
ment and prevention are effectiveness at improving TB
free survival and reducing childhood M. tuberculosis
prevalence, and can contribute to efforts to achieve the
End-TB strategy goals.
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